A robust and promising pipeline
Patients who suffer from many Complement-mediated rare diseases have few, if any, treatment options. By developing innovative medicines designed to specifically inhibit the Classical pathway of the Complement system, True North is addressing the treatment needs of these patients. Our novel humanized antibodies target C1s, selectively inhibiting the Classical pathway. Due to the numerous diseases in which Classical pathway activity has been implicated in driving pathology, a pipeline of product opportunities exist for our antibodies.
Because True North’s drug candidates are designed to inhibit the Classical pathway proximally, our proprietary antibodies offer an advantage over other therapeutic approaches that act by inhibiting the Complement system further downstream. Our drug candidates address a pathway that is fundamental in driving numerous rare diseases in hematology, transplantation, dermatology, and other areas.
The company’s most advanced product candidate, TNT009, is a first-in-class antibody that selectively inhibits C1s, a Classical pathway-specific enzyme. TNT009 is currently in clinical development for the treatment of rare diseases in hematology, transplantation, and dermatology. With a unique mechanism of action and high target specificity, TNT009 inhibits the dysregulation of the Classical pathway while maintaining the important immune surveillance provided by the other two Complement system pathways, the Alternative pathway and Lectin pathway.
Next-generation anti-C1s antibodies
True North is also investigating other treatment options for a wide range of Classical Complement-mediated diseases. To this end, we are developing additional monoclonal antibodies to inhibit Classical Complement activity with other molecular targets and pharmacologic properties.